Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Sage Therapeutics to Present at the Neurocritical Care Society 14th Annual Meeting

Sage Therapeutics
Posted on: 16 Sep 16

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming poster presentations at the Neurocritical Care Society 14th Annual Meeting, taking place from September 15-18 in National Harbor, Md.

Below is the schedule for the poster presentations:

   

Date:

Friday, September 16, 2016

Poster Presentation Time:

5:30 p.m. – 6:30 p.m. EDT

Location:

Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number:

10
 

Title:

Preclinical Pharmacology and Pharmacodynamic Interactions of SAGE-547: Relevance to Super-Refractory Status Epilepticus
 
   

Date:

Friday, September 16, 2016

Poster Presentation Time:

5:30 p.m. – 6:30 p.m. EDT

Location:

Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number:

168
 

Title:

Pharmacokinetics of SAGE-547 in Patients with Super-Refractory Status Epilepticus
 
   

Date:

Friday, September 16, 2016

Poster Presentation Time:

5:30 p.m. – 6:30 p.m. EDT

Location:

Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number:

172
 

Title:

SAGE-547 (allopregnanolone injection) for the Treatment of Super-Refractory Status Epilepticus: Response and Relationship to Underlying Patient Characteristics
 
   

Date:

Friday, September 16, 2016

Poster Presentation Time:

5:30 p.m. – 6:30 p.m. EDT

Location:

Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number:

174
 

Title:

Phase 1/2 Open-Label Data Suggest that Heterogeneity of Presentation and High Burden of Comorbid Illness Do Not Impact the Activity of SAGE-547 in Patients with Super-Refractory Status Epilepticus
 
   

Date:

Saturday, September 17, 2016

Poster Presentation Time:

5:30 p.m. – 6:30 p.m. EDT

Location:

Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number:

165
 

Title:

Hemodynamic Properties of SAGE-547 in Patients with Super-Refractory Status Epilepticus: Results from a Phase 1/2 Clinical Trial
 

In addition, Sage will host a lunch symposium featuring key opinion leaders. Details are as follows:

   

Date:

Saturday, September 17, 2016

Time:

12:00 p.m. – 1:00 p.m. EDT

Location:

Gaylord National Resort & Convention Center, Maryland Ballroom C
 

Title:

Diagnosis and Management of Super-Refractory Status Epilepticus
 

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160916005142/en/

Business Wire
www.businesswire.com

Last updated on: 16/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.